Market Research Logo

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016’, provides in depth analysis on Human Papillomavirus Protein E6 (E6) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Papillomavirus Protein E6 (E6), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
  • The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Protein E6 (E6) Overview
Therapeutics Development
Human Papillomavirus Protein E6 (E6) - Products under Development by Stage of Development
Human Papillomavirus Protein E6 (E6) - Products under Development by Therapy Area
Human Papillomavirus Protein E6 (E6) - Products under Development by Indication
Human Papillomavirus Protein E6 (E6) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Human Papillomavirus Protein E6 (E6) - Products under Development by Companies
Human Papillomavirus Protein E6 (E6) - Products under Development by Universities/Institutes
Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
BioNTech AG
Cancer Research Technology Limited
Etubics Corporation
Genexine, Inc.
Inovio Pharmaceuticals, Inc.
MedImmune, LLC
Selecta Biosciences, Inc.
Tomegavax, Inc.
Transgene SA
Human Papillomavirus Protein E6 (E6) - Drug Profiles
Antibodies to Target E6 for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CIN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Protein E6 (E6) - Dormant Projects
Human Papillomavirus Protein E6 (E6) - Discontinued Products
Human Papillomavirus Protein E6 (E6) - Featured News & Press Releases
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress
Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan
Nov 05, 2015: Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial
Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as Best Therapeutic Vaccine by World Vaccine Congress
Apr 09, 2015: Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients
Dec 23, 2014: Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology
Oct 30, 2014: Genexine’s HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial
Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV
Jul 01, 2013: Etubics Awarded Grant To Develop HPV Immunotherapy Targeting Head & Neck Cancer
Nov 26, 2012: Inovio Pharma's Cytomegalovirus Synthetic Vaccine Generates Strong And Broad T-cell Responses In Preclinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by BioNTech AG, H2 2016
Pipeline by Cancer Research Technology Limited, H2 2016
Pipeline by Etubics Corporation, H2 2016
Pipeline by Genexine, Inc., H2 2016
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
Pipeline by MedImmune, LLC, H2 2016
Pipeline by Selecta Biosciences, Inc., H2 2016
Pipeline by Tomegavax, Inc., H2 2016
Pipeline by Transgene SA, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report